Reis Tarcisio A, Cataneo Daniele C, Cataneo Antônio Jose Maria
Post-Graduation Program on Medicine, Botucatu School of Medicine, São Paulo State University, UNESP, São Paulo, Brazil.
Department of Surgery, Botucatu School of Medicine, São Paulo State University, UNESP, São Paulo, Brazil.
Interact Cardiovasc Thorac Surg. 2019 Dec 1;29(6):867-875. doi: 10.1093/icvts/ivz186.
Our goal was to evaluate, through a systematic review, the efficacy of plasmapheresis in the preoperative preparation of the patient for a thymectomy for the treatment of myasthenia gravis.
MEDLINE, Embase, LILACS, Scopus and CENTRAL databases were searched. The following outcomes were evaluated: myasthenic crisis, mortality, pneumonia, bleeding, use of mechanical ventilation, length of hospital stay and intensive care unit (ICU) stay. RevMan 5.3 software provided by the Cochrane Collaboration was used for the meta-analysis.
The total number of patients evaluated in the 7 included studies was 360. Plasmapheresis during the preoperative period did not decrease the myasthenic crisis [risk ratio (RR) 0.36, 95% confidence interval (CI) 0.08-1.66; I2 = 44%; 5 studies, 243 patients]. There was also no change in the mortality rate (RR 0.7, 95% CI 0.11-4.62; I2 = 0%; 3 studies, 172 patients) or pneumonia cases (RR 0.28, 95% CI 0.07-1.09; I2 = 27%; 5 studies, 272 patients). Bleeding was greater in patients who underwent plasmapheresis (mean difference 34.34 ml; 95% CI 24.93-43.75; I2 = 0%). We evaluated the following outcomes: need for mechanical ventilation, hospital stay, ICU stay and mechanical ventilation, but these outcomes were not adequate to perform the meta-analysis due to the high heterogeneity among the studies. Subgroup analysis showed that plasmapheresis performed during the preoperative period in patients with severe disease (Osserman III and IV) decreased the myasthenic crisis postoperatively (RR 0.12, 95% CI 0.02-0.65; I2 = 63%).
Plasmapheresis may reduce the myasthenic crisis during the postoperative period in patients with severe disease but may produce little or no difference in patients with mild clinical expression of the disease.
我们的目标是通过系统评价,评估血浆置换在重症肌无力患者胸腺切除术术前准备中的疗效。
检索了MEDLINE、Embase、LILACS、Scopus和CENTRAL数据库。评估了以下结局:肌无力危象、死亡率、肺炎、出血、机械通气的使用、住院时间和重症监护病房(ICU)住院时间。使用Cochrane协作网提供的RevMan 5.3软件进行荟萃分析。
纳入的7项研究中评估的患者总数为360例。术前进行血浆置换并未降低肌无力危象的发生率[风险比(RR)0.36,95%置信区间(CI)0.08 - 1.66;I² = 44%;5项研究,243例患者]。死亡率(RR 0.7,95% CI 0.11 - 4.62;I² = 0%;3项研究,172例患者)或肺炎病例数(RR 0.28,95% CI 0.07 - 1.09;I² = 27%;5项研究,272例患者)也没有变化。接受血浆置换的患者出血更多(平均差异34.34 ml;95% CI 24.93 - 43.75;I² = 0%)。我们评估了以下结局:机械通气需求、住院时间、ICU住院时间和机械通气情况,但由于研究间异质性高,这些结局不足以进行荟萃分析。亚组分析显示,术前对重症(Osserman III和IV型)患者进行血浆置换可降低术后肌无力危象的发生率(RR 0.12,95% CI 0.02 - 0.65;I² = 63%)。
血浆置换可能会降低重症患者术后的肌无力危象,但对疾病临床表现较轻的患者可能几乎没有差异或无差异。